Details for Patent: RE48285
✉ Email this page to a colleague
Which drugs does patent RE48285 protect, and when does it expire?
Patent RE48285 protects OJJAARA and is included in one NDA.
This patent has fifty-two patent family members in thirty-one countries.
Drugs Protected by US Patent RE48285
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-001 | Sep 15, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ⤷ Try a Trial | ||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-002 | Sep 15, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ⤷ Try a Trial | ||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE48285
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 100818 | ⤷ Try a Trial | |||
Australia | 2015274554 | ⤷ Try a Trial | |||
Brazil | 112016028749 | ⤷ Try a Trial | |||
Canada | 2951883 | ⤷ Try a Trial | |||
China | 106458929 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |